Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS and Hengrui Pharma are building a 13-asset pipeline in a deal worth up to $15.2 billion across oncology, hematology and immunology. Hengrui contributes…
Bristol Myers Squibb is paying Chinese drugmaker Jiangsu Hengrui Pharmaceutical $600 million upfront with potential milestone payments that could push the…
Bristol Myers Squibb and Hengrui forge a $15.2 billion strategic alliance reshaping the China-out licensing landscape. The deal follows recent precedents…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS and Hengrui entered into a multi-asset strategic collaboration and license covering 13 early-stage programs (4 Hengrui oncology/hematology assets, 4 BMS immunology assets, 5 joint-discovery programs). BMS pays Hengrui $600M upfront, $175M first-anniversary, $175M contingent second-anniversary (i.e., up to $950M near-term), plus option-exercise fees and milestones bringing total potential value to ~$15.2B, plus tiered royalties. One of the largest pharma-China alliances on record.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (this deal) | 2026 | $15.2B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2026 deals · Bristol-Myers Squibb Company deals · Hematology deals